Age-Related Macular Degeneration (AMD): Types, Risk Factors, Treatments, and Monitoring

Age-related macular degeneration (AMD) is the leading cause of irreversible central vision loss in adults ≥50. It spares peripheral vision, so total blindness is rare, but functional independence can be severely compromised.

Two Major Phenotypes

  • Dry (atrophic) AMD — 85–90%: Drusen accumulation → RPE atrophy → geographic atrophy (GA). Slow, insidious progression over years.
  • Wet (neovascular) AMD — 10–15%: Choroidal neovascularization (CNV) breaches Bruch's membrane → fluid/blood leakage → rapid vision loss (weeks–months). Accounts for 90% of AMD-related legal blindness.

Risk Factors

  • Non-modifiable: Age, genetics (CFH, ARMS2), female sex, light iris, family history.
  • Modifiable: Smoking (strongest, 2–4× risk), obesity, hypertension, dyslipidemia, poor diet (low lutein/zeaxanthin, high glycemic index), excessive blue-light exposure.

Symptoms

  • Metamorphopsia (straight lines wavy) — hallmark of CNV
  • Central scotoma, blurred reading vision
  • Delayed dark adaptation, color desaturation
  • Charles Bonnet syndrome (visual hallucinations) in advanced loss

Treatments

TypeDry AMDWet AMD
Approved disease-modifyingPegcetacoplan, avacincaptad pegol (GA only)Anti-VEGF: aflibercept, ranibizumab, bevacizumab, faricimab, brolucizumab
NutritionalAREDS2 formula (lutein/zeaxanthin, vitamins C/E, zinc, copper)AREDS2 may slow fellow-eye progression
ProceduralLow-vision rehabPhotodynamic therapy (verteporfin) — niche; laser photocoagulation — historical

Monitoring

  • Dilated exam + OCT annually (intermediate) or q4–12wk (active wet).
  • Home Amsler grid daily; ForeseeHome monitoring (FDA-cleared) for high-risk.
  • Prompt evaluation for new distortion = possible CNV conversion.

Early detection + prompt anti-VEGF for wet AMD + complement inhibition for GA + lifestyle modification = best visual outcomes.

Eye & Vision Disorders - Related Articles